{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T22:07:01Z","timestamp":1792447621101,"version":"4.5.0"},"reference-count":69,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,3,11]],"date-time":"2024-03-11T00:00:00Z","timestamp":1710115200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,3,11]],"date-time":"2024-03-11T00:00:00Z","timestamp":1710115200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000864","name":"Michael J. Fox Foundation for Parkinson's Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000864","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000957","name":"Alzheimer's Association","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000957","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Knight Initiative for Brain Resilience"},{"name":"NIH"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Acta Neuropathol"],"published-print":{"date-parts":[[2024,6]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Parkinson\u2019s disease (PD) starts at the molecular and cellular level long before motor symptoms appear, yet there are no early-stage molecular biomarkers for diagnosis, prognosis prediction, or monitoring therapeutic response. This lack of biomarkers greatly impedes patient care and translational research\u2014<jats:sc>l<\/jats:sc>-DOPA remains the standard of care more than 50\u00a0years after its introduction. Here, we performed a large-scale, multi-tissue, and multi-platform proteomics study to identify new biomarkers for early diagnosis and disease monitoring in PD. We analyzed 4877 cerebrospinal fluid, blood plasma, and urine samples from participants across seven cohorts using three orthogonal proteomics methods: Olink proximity extension assay, SomaScan aptamer precipitation assay, and liquid chromatography\u2013mass spectrometry proteomics. We discovered that hundreds of proteins were upregulated in the CSF, blood, or urine of PD patients, prodromal PD patients with DAT deficit and REM sleep behavior disorder or anosmia, and non-manifesting genetic carriers of LRRK2 and GBA mutations. We nominate multiple novel hits across our analyses as promising markers of early PD, including DOPA decarboxylase (DDC), also known as<jats:sc>l<\/jats:sc>-aromatic acid decarboxylase (AADC), sulfatase-modifying factor 1 (SUMF1), dipeptidyl peptidase 2\/7 (DPP7), glutamyl aminopeptidase (ENPEP), WAP four-disulfide core domain 2 (WFDC2), and others. DDC, which catalyzes the final step in dopamine synthesis, particularly stands out as a novel hit with a compelling mechanistic link to PD pathogenesis. DDC is consistently upregulated in the CSF and urine of treatment-na\u00efve PD, prodromal PD, and GBA or LRRK2 carrier participants by all three proteomics methods. We show that CSF DDC levels correlate with clinical symptom severity in treatment-na\u00efve PD patients and can be used to accurately diagnose PD and prodromal PD. This suggests that urine and CSF DDC could be a promising diagnostic and prognostic marker with utility in both clinical care and translational research.<\/jats:p>","DOI":"10.1007\/s00401-024-02706-0","type":"journal-article","created":{"date-parts":[[2024,3,11]],"date-time":"2024-03-11T20:02:34Z","timestamp":1710187354000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":113,"title":["Comprehensive proteomics of CSF, plasma, and urine identify DDC and other biomarkers of early Parkinson\u2019s disease"],"prefix":"10.1007","volume":"147","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7790-2801","authenticated-orcid":false,"given":"Jarod","family":"Rutledge","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benoit","family":"Lehallier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pardis","family":"Zarifkar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patricia Moran","family":"Losada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marian","family":"Shahid-Besanti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dan","family":"Western","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Priyanka","family":"Gorijala","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sephira","family":"Ryman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maya","family":"Yutsis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gayle K.","family":"Deutsch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth","family":"Mormino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandra","family":"Trelle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony D.","family":"Wagner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Geoffrey A.","family":"Kerchner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lu","family":"Tian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlos","family":"Cruchaga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victor W.","family":"Henderson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas J.","family":"Montine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Per","family":"Borghammer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tony","family":"Wyss-Coray","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathleen L.","family":"Poston","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,3,11]]},"reference":[{"key":"2706_CR1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0095192","volume":"9","author":"E Assarsson","year":"2014","unstructured":"Assarsson E, Lundberg M, Holmquist G, Bj\u00f6rkesten J, Thorsen SB, Ekman D et al (2014) Homogenous 96-Plex PEA immunoassay exhibiting high sensitivity, specificity, and excellent scalability. PLoS ONE 9:e95192. https:\/\/doi.org\/10.1371\/journal.pone.0095192","journal-title":"PLoS ONE"},{"key":"2706_CR2","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1016\/S0197-4580(02)00065-9","volume":"24","author":"H Braak","year":"2003","unstructured":"Braak H, Tredici KD, R\u00fcb U, de Vos RAI, Jansen Steur ENH, Braak E (2003) Staging of brain pathology related to sporadic Parkinson\u2019s disease. Neurobiol Aging 24:197\u2013211. https:\/\/doi.org\/10.1016\/S0197-4580(02)00065-9","journal-title":"Neurobiol Aging"},{"key":"2706_CR3","doi-asserted-by":"publisher","first-page":"197","DOI":"10.14283\/jpad.2022.30","volume":"9","author":"S Budd Haeberlein","year":"2022","unstructured":"Budd Haeberlein S, Aisen PS, Barkhof F, Chalkias S, Chen T, Cohen S et al (2022) Two randomized phase 3 studies of aducanumab in early Alzheimer\u2019s disease. J Prev Alzheimers Dis 9:197\u2013210. https:\/\/doi.org\/10.14283\/jpad.2022.30","journal-title":"J Prev Alzheimers Dis"},{"key":"2706_CR4","doi-asserted-by":"publisher","first-page":"5635","DOI":"10.1038\/s41467-023-41122-y","volume":"14","author":"M del Campo","year":"2023","unstructured":"del Campo M, Vermunt L, Peeters CFW, Sieben A, Hok-A-Hin YS, Lle\u00f3 A et al (2023) CSF proteome profiling reveals biomarkers to discriminate dementia with Lewy bodies from Alzheimer\u00b4s disease. Nat Commun 14:5635. https:\/\/doi.org\/10.1038\/s41467-023-41122-y","journal-title":"Nat Commun"},{"key":"2706_CR5","doi-asserted-by":"publisher","first-page":"704","DOI":"10.1002\/ana.25450","volume":"85","author":"CW Christine","year":"2019","unstructured":"Christine CW, Bankiewicz KS, Van Laar AD, Richardson RM, Ravina B, Kells AP et al (2019) Magnetic resonance imaging\u2013guided phase 1 trial of putaminal AADC gene therapy for Parkinson\u2019s disease. Ann Neurol 85:704\u2013714. https:\/\/doi.org\/10.1002\/ana.25450","journal-title":"Ann Neurol"},{"key":"2706_CR6","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0169965","volume":"12","author":"A Ciesielska","year":"2017","unstructured":"Ciesielska A, Samaranch L, Sebastian WS, Dickson DW, Goldman S, Forsayeth J et al (2017) Depletion of AADC activity in caudate nucleus and putamen of Parkinson\u2019s disease patients; implications for ongoing AAV2-AADC gene therapy trial. PLoS ONE 12:e0169965. https:\/\/doi.org\/10.1371\/journal.pone.0169965","journal-title":"PLoS ONE"},{"key":"2706_CR7","doi-asserted-by":"publisher","first-page":"1318","DOI":"10.1126\/science.aaz1776","volume":"369","author":"Consortium TGte","year":"2020","unstructured":"Consortium TGte (2020) The GTEx Consortium atlas of genetic regulatory effects across human tissues. Science 369:1318\u20131330. https:\/\/doi.org\/10.1126\/science.aaz1776","journal-title":"Science"},{"key":"2706_CR8","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1146\/annurev.genom.6.080604.162334","volume":"6","author":"G Diez-Roux","year":"2005","unstructured":"Diez-Roux G, Ballabio A (2005) Sulfatases and human disease. Annu Rev Genom Hum Genet 6:355\u2013379. https:\/\/doi.org\/10.1146\/annurev.genom.6.080604.162334","journal-title":"Annu Rev Genom Hum Genet"},{"key":"2706_CR9","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1056\/NEJMoa2212948","volume":"388","author":"CH van Dyck","year":"2023","unstructured":"van Dyck CH, Swanson CJ, Aisen P, Bateman RJ, Chen C, Gee M et al (2023) Lecanemab in early Alzheimer\u2019s disease. N Engl J Med 388:9\u201321. https:\/\/doi.org\/10.1056\/NEJMoa2212948","journal-title":"N Engl J Med"},{"key":"2706_CR10","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1016\/j.dadm.2017.04.007","volume":"8","author":"S Engelborghs","year":"2017","unstructured":"Engelborghs S, Niemantsverdriet E, Struyfs H, Blennow K, Brouns R, Comabella M et al (2017) Consensus guidelines for lumbar puncture in patients with neurological diseases. Alzheimers Dement Diagn Assess Dis Monit 8:111\u2013126. https:\/\/doi.org\/10.1016\/j.dadm.2017.04.007","journal-title":"Alzheimers Dement Diagn Assess Dis Monit"},{"key":"2706_CR11","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1016\/S0149-7634(00)00028-2","volume":"24","author":"M Gesi","year":"2000","unstructured":"Gesi M, Soldani P, Giorgi FS, Santinami A, Bonaccorsi I, Fornai F (2000) The role of the locus coeruleus in the development of Parkinson\u2019s disease. Neurosci Biobehav Rev 24:655\u2013668. https:\/\/doi.org\/10.1016\/S0149-7634(00)00028-2","journal-title":"Neurosci Biobehav Rev"},{"key":"2706_CR12","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1016\/j.parkreldis.2006.08.006","volume":"13","author":"MF Ghilardi","year":"2007","unstructured":"Ghilardi MF, Feigin AS, Battaglia F, Silvestri G, Mattis P, Eidelberg D et al (2007) l-Dopa infusion does not improve explicit sequence learning in Parkinson\u2019s disease. Parkinsonism Relat Disord 13:146\u2013151. https:\/\/doi.org\/10.1016\/j.parkreldis.2006.08.006","journal-title":"Parkinsonism Relat Disord"},{"key":"2706_CR13","doi-asserted-by":"publisher","first-page":"2129","DOI":"10.1002\/mds.22340","volume":"23","author":"CG Goetz","year":"2008","unstructured":"Goetz CG, Tilley BC, Shaftman SR, Stebbins GT, Fahn S, Martinez-Martin P et al (2008) Movement Disorder Society-sponsored revision of the Unified Parkinson\u2019s Disease Rating Scale (MDS-UPDRS): Scale presentation and clinimetric testing results. Mov Disord 23:2129\u20132170. https:\/\/doi.org\/10.1002\/mds.22340","journal-title":"Mov Disord"},{"key":"2706_CR14","doi-asserted-by":"publisher","first-page":"690","DOI":"10.1002\/mds.21894","volume":"23","author":"CG Goetz","year":"2008","unstructured":"Goetz CG, Wuu J, McDermott MP, Adler CH, Fahn S, Freed CR et al (2008) Placebo response in Parkinson\u2019s disease: comparisons among 11 trials covering medical and surgical interventions. Mov Disord 23:690\u2013699. https:\/\/doi.org\/10.1002\/mds.21894","journal-title":"Mov Disord"},{"key":"2706_CR15","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0015004","volume":"5","author":"L Gold","year":"2010","unstructured":"Gold L, Ayers D, Bertino J, Bock C, Bock A, Brody EN et al (2010) Aptamer-based multiplexed proteomic technology for biomarker discovery. PLoS ONE 5:e15004. https:\/\/doi.org\/10.1371\/journal.pone.0015004","journal-title":"PLoS ONE"},{"key":"2706_CR16","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1111\/j.1468-1331.2007.01727.x","volume":"14","author":"M Guttman","year":"2007","unstructured":"Guttman M, Boileau I, Warsh J, Saint-Cyr JA, Ginovart N, McCluskey T et al (2007) Brain serotonin transporter binding in non-depressed patients with Parkinson\u2019s disease. Eur J Neurol 14:523\u2013528. https:\/\/doi.org\/10.1111\/j.1468-1331.2007.01727.x","journal-title":"Eur J Neurol"},{"key":"2706_CR17","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1093\/bioinformatics\/btaa687","volume":"37","author":"GE Hoffman","year":"2021","unstructured":"Hoffman GE, Roussos P (2021) Dream: powerful differential expression analysis for repeated measures designs. Bioinformatics 37:192\u2013201. https:\/\/doi.org\/10.1093\/bioinformatics\/btaa687","journal-title":"Bioinformatics"},{"key":"2706_CR18","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1212\/WNL.0000000000002923","volume":"87","author":"CR Jack","year":"2016","unstructured":"Jack CR, Bennett DA, Blennow K, Carrillo MC, Feldman HH, Frisoni GB et al (2016) A\/T\/N: an unbiased descriptive classification scheme for Alzheimer disease biomarkers. Neurology 87:539\u2013547. https:\/\/doi.org\/10.1212\/WNL.0000000000002923","journal-title":"Neurology"},{"key":"2706_CR19","doi-asserted-by":"publisher","first-page":"1","DOI":"10.18637\/jss.v082.i13","volume":"82","author":"A Kuznetsova","year":"2017","unstructured":"Kuznetsova A, Brockhoff PB, Christensen RHB (2017) lmerTest Package: tests in linear mixed effects models. J Stat Softw 82:1\u201326. https:\/\/doi.org\/10.18637\/jss.v082.i13","journal-title":"J Stat Softw"},{"key":"2706_CR20","doi-asserted-by":"publisher","DOI":"10.1080\/713609354","author":"A-M Lambeir","year":"2003","unstructured":"Lambeir A-M, Durinx C, Scharp\u00e9 S, Meester ID (2003) Dipeptidyl-peptidase IV from Bench to bedside: an update on structural properties, functions, and clinical aspects of the enzyme DPP IV. Crit Rev Clin Lab Sci. https:\/\/doi.org\/10.1080\/713609354","journal-title":"Crit Rev Clin Lab Sci"},{"key":"2706_CR21","doi-asserted-by":"publisher","first-page":"1843","DOI":"10.1038\/s41591-019-0673-2","volume":"25","author":"B Lehallier","year":"2019","unstructured":"Lehallier B, Gate D, Schaum N, Nanasi T, Lee SE, Yousef H et al (2019) Undulating changes in human plasma proteome profiles across the lifespan. Nat Med 25:1843\u20131850. https:\/\/doi.org\/10.1038\/s41591-019-0673-2","journal-title":"Nat Med"},{"key":"2706_CR22","doi-asserted-by":"publisher","first-page":"857","DOI":"10.1001\/archgenpsychiatry.2010.88","volume":"67","author":"SC Lidstone","year":"2010","unstructured":"Lidstone SC, Schulzer M, Dinelle K, Mak E, Sossi V, Ruth TJ et al (2010) Effects of expectation on placebo-induced dopamine release in Parkinson Disease. Arch Gen Psychiatry 67:857\u2013865. https:\/\/doi.org\/10.1001\/archgenpsychiatry.2010.88","journal-title":"Arch Gen Psychiatry"},{"key":"2706_CR23","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1002\/mds.10459","volume":"18","author":"I Litvan","year":"2003","unstructured":"Litvan I, Bhatia KP, Burn DJ, Goetz CG, Lang AE, McKeith I et al (2003) SIC Task Force appraisal of clinical diagnostic criteria for parkinsonian disorders. Mov Disord 18:467\u2013486. https:\/\/doi.org\/10.1002\/mds.10459","journal-title":"Mov Disord"},{"key":"2706_CR24","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1002\/mds.24893","volume":"27","author":"I Litvan","year":"2012","unstructured":"Litvan I, Goldman JG, Tr\u00f6ster AI, Schmand BA, Weintraub D, Petersen RC et al (2012) Diagnostic criteria for mild cognitive impairment in Parkinson\u2019s disease: Movement Disorder Society Task Force guidelines. Mov Disord 27:349\u2013356. https:\/\/doi.org\/10.1002\/mds.24893","journal-title":"Mov Disord"},{"key":"2706_CR25","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1016\/j.bcp.2006.04.009","volume":"72","author":"M-B Maes","year":"2006","unstructured":"Maes M-B, Martinet W, Schrijvers DM, Van der Veken P, De Meyer GRY, Augustyns K et al (2006) Dipeptidyl peptidase II and leukocyte cell death. Biochem Pharmacol 72:70\u201379. https:\/\/doi.org\/10.1016\/j.bcp.2006.04.009","journal-title":"Biochem Pharmacol"},{"key":"2706_CR26","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/j.cca.2007.01.024","volume":"380","author":"M-B Maes","year":"2007","unstructured":"Maes M-B, Scharp\u00e9 S, De Meester I (2007) Dipeptidyl peptidase II (DPPII), a review. Clin Chim Acta 380:31\u201349. https:\/\/doi.org\/10.1016\/j.cca.2007.01.024","journal-title":"Clin Chim Acta"},{"key":"2706_CR27","doi-asserted-by":"publisher","DOI":"10.3390\/ijms23169184","author":"C Malloy","year":"2022","unstructured":"Malloy C, Ahern M, Lin L, Hoffman DA (2022) Neuronal roles of the multifunctional protein dipeptidyl peptidase-like 6 (DPP6). Int J Mol Sci. https:\/\/doi.org\/10.3390\/ijms23169184","journal-title":"Int J Mol Sci"},{"key":"2706_CR28","doi-asserted-by":"publisher","first-page":"1460","DOI":"10.1002\/acn3.644","volume":"5","author":"K Marek","year":"2018","unstructured":"Marek K, Chowdhury S, Siderowf A, Lasch S, Coffey CS, Caspell-Garcia C et al (2018) The Parkinson\u2019s progression markers initiative (PPMI)\u2014establishing a PD biomarker cohort. Ann Clin Transl Neurol 5:1460\u20131477. https:\/\/doi.org\/10.1002\/acn3.644","journal-title":"Ann Clin Transl Neurol"},{"key":"2706_CR29","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1016\/j.pneurobio.2011.09.005","volume":"95","author":"K Marek","year":"2011","unstructured":"Marek K, Jennings D, Lasch S, Siderowf A, Tanner C, Simuni T et al (2011) The Parkinson Progression Marker Initiative (PPMI). Prog Neurobiol 95:629\u2013635. https:\/\/doi.org\/10.1016\/j.pneurobio.2011.09.005","journal-title":"Prog Neurobiol"},{"key":"2706_CR30","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1016\/j.jalz.2011.03.005","volume":"7","author":"GM McKhann","year":"2011","unstructured":"McKhann GM, Knopman DS, Chertkow H, Hyman BT, Jack CR, Kawas CH et al (2011) The diagnosis of dementia due to Alzheimer\u2019s disease: Recommendations from the National Institute on Aging-Alzheimer\u2019s Association workgroups on diagnostic guidelines for Alzheimer\u2019s disease. Alzheimers Dement J Alzheimers Assoc 7:263\u2013269. https:\/\/doi.org\/10.1016\/j.jalz.2011.03.005","journal-title":"Alzheimers Dement J Alzheimers Assoc"},{"key":"2706_CR31","doi-asserted-by":"publisher","first-page":"1099","DOI":"10.1056\/NEJMoa2204705","volume":"387","author":"TM Miller","year":"2022","unstructured":"Miller TM, Cudkowicz ME, Genge A, Shaw PJ, Sobue G, Bucelli RC et al (2022) Trial of Antisense Oligonucleotide Tofersen for SOD1 ALS. N Engl J Med 387:1099\u20131110. https:\/\/doi.org\/10.1056\/NEJMoa2204705","journal-title":"N Engl J Med"},{"key":"2706_CR32","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1017\/S1041610297004754","volume":"9","author":"DW Molloy","year":"1997","unstructured":"Molloy DW, Standish TIM (1997) A guide to the standardized mini-mental state examination. Int Psychogeriatr 9:87\u201394. https:\/\/doi.org\/10.1017\/S1041610297004754","journal-title":"Int Psychogeriatr"},{"key":"2706_CR33","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1111\/j.1532-5415.2005.53221.x","volume":"53","author":"ZS Nasreddine","year":"2005","unstructured":"Nasreddine ZS, Phillips NA, B\u00e9dirian V, Charbonneau S, Whitehead V, Collin I et al (2005) The Montreal Cognitive Assessment, MoCA: a brief screening tool for mild cognitive impairment. J Am Geriatr Soc 53:695\u2013699. https:\/\/doi.org\/10.1111\/j.1532-5415.2005.53221.x","journal-title":"J Am Geriatr Soc"},{"key":"2706_CR34","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1016\/j.nicl.2017.09.004","volume":"16","author":"B Ng","year":"2017","unstructured":"Ng B, Varoquaux G, Poline JB, Thirion B, Greicius MD, Poston KL (2017) Distinct alterations in Parkinson\u2019s medication-state and disease-state connectivity. NeuroImage Clin 16:575\u2013585. https:\/\/doi.org\/10.1016\/j.nicl.2017.09.004","journal-title":"NeuroImage Clin"},{"key":"2706_CR35","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1038\/s41586-023-06802-1","volume":"624","author":"HS-H Oh","year":"2023","unstructured":"Oh HS-H, Rutledge J, Nachun D, P\u00e1lovics R, Abiose O, Moran-Losada P et al (2023) Organ aging signatures in the plasma proteome track health and disease. Nature 624:164\u2013172. https:\/\/doi.org\/10.1038\/s41586-023-06802-1","journal-title":"Nature"},{"key":"2706_CR36","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1002\/acn3.51280","volume":"8","author":"CD Orr\u00f9","year":"2020","unstructured":"Orr\u00f9 CD, Ma TC, Hughson AG, Groveman BR, Srivastava A, Galasko D et al (2020) A rapid \u03b1-synuclein seed assay of Parkinson\u2019s disease CSF panel shows high diagnostic accuracy. Ann Clin Transl Neurol 8:374\u2013384. https:\/\/doi.org\/10.1002\/acn3.51280","journal-title":"Ann Clin Transl Neurol"},{"key":"2706_CR37","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1016\/S1474-4422(19)30024-9","volume":"18","author":"L Parnetti","year":"2019","unstructured":"Parnetti L, Gaetani L, Eusebi P, Paciotti S, Hansson O, El-Agnaf O et al (2019) CSF and blood biomarkers for Parkinson\u2019s disease. Lancet Neurol 18:573\u2013586. https:\/\/doi.org\/10.1016\/S1474-4422(19)30024-9","journal-title":"Lancet Neurol"},{"key":"2706_CR38","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1186\/s40035-023-00374-w","volume":"12","author":"W Paslawski","year":"2023","unstructured":"Paslawski W, Khosousi S, Hertz E, Markaki I, Boxer A, Svenningsson P (2023) Large-scale proximity extension assay reveals CSF midkine and DOPA decarboxylase as supportive diagnostic biomarkers for Parkinson\u2019s disease. Transl Neurodegener 12:42. https:\/\/doi.org\/10.1186\/s40035-023-00374-w","journal-title":"Transl Neurodegener"},{"key":"2706_CR39","doi-asserted-by":"publisher","first-page":"1201","DOI":"10.1038\/s43587-023-00478-y","volume":"3","author":"JB Pereira","year":"2023","unstructured":"Pereira JB, Kumar A, Hall S, Palmqvist S, Stomrud E, Bali D et al (2023) DOPA decarboxylase is an emerging biomarker for Parkinsonian disorders including preclinical Lewy body disease. Nat Aging 3:1201\u20131209. https:\/\/doi.org\/10.1038\/s43587-023-00478-y","journal-title":"Nat Aging"},{"key":"2706_CR40","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1111\/j.1365-2796.2004.01388.x","volume":"256","author":"RC Petersen","year":"2004","unstructured":"Petersen RC (2004) Mild cognitive impairment as a diagnostic entity. J Intern Med 256:183\u2013194. https:\/\/doi.org\/10.1111\/j.1365-2796.2004.01388.x","journal-title":"J Intern Med"},{"key":"2706_CR41","doi-asserted-by":"publisher","first-page":"8627","DOI":"10.1073\/pnas.96.15.8627","volume":"96","author":"CTN Pham","year":"1999","unstructured":"Pham CTN, Ley TJ (1999) Dipeptidyl peptidase I is required for the processing and activation of granzymes A and B in vivo. Proc Natl Acad Sci 96:8627\u20138632. https:\/\/doi.org\/10.1073\/pnas.96.15.8627","journal-title":"Proc Natl Acad Sci"},{"key":"2706_CR42","doi-asserted-by":"publisher","first-page":"S65","DOI":"10.1212\/WNL.0b013e31819908ce","volume":"72","author":"W Poewe","year":"2009","unstructured":"Poewe W (2009) Treatments for Parkinson disease\u2014past achievements and current clinical needs. Neurology 72:S65\u2013S73. https:\/\/doi.org\/10.1212\/WNL.0b013e31819908ce","journal-title":"Neurology"},{"key":"2706_CR43","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1093\/brain\/awab431","volume":"145","author":"I Poggiolini","year":"2022","unstructured":"Poggiolini I, Gupta V, Lawton M, Lee S, El-Turabi A, Querejeta-Coma A et al (2022) Diagnostic value of cerebrospinal fluid alpha-synuclein seed quantification in synucleinopathies. Brain 145:584\u2013595. https:\/\/doi.org\/10.1093\/brain\/awab431","journal-title":"Brain"},{"key":"2706_CR44","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1002\/ana.23872","volume":"74","author":"JK Qiang","year":"2013","unstructured":"Qiang JK, Wong YC, Siderowf A, Hurtig HI, Xie SX, Lee VM-Y et al (2013) Plasma apolipoprotein A1 as a biomarker for Parkinson disease. Ann Neurol 74:119\u2013127. https:\/\/doi.org\/10.1002\/ana.23872","journal-title":"Ann Neurol"},{"key":"2706_CR45","doi-asserted-by":"publisher","first-page":"3191","DOI":"10.1093\/brain\/awx285","volume":"140","author":"LA Robak","year":"2017","unstructured":"Robak LA, Jansen IE, van Rooij J, Uitterlinden AG, Kraaij R, Jankovic J et al (2017) Excessive burden of lysosomal storage disorder gene variants in Parkinson\u2019s disease. Brain 140:3191\u20133203. https:\/\/doi.org\/10.1093\/brain\/awx285","journal-title":"Brain"},{"key":"2706_CR46","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1186\/1471-2105-12-77","volume":"12","author":"X Robin","year":"2011","unstructured":"Robin X, Turck N, Hainard A, Tiberti N, Lisacek F, Sanchez J-C et al (2011) pROC: an open-source package for R and S+ to analyze and compare ROC curves. BMC Bioinform 12:77","journal-title":"BMC Bioinform"},{"key":"2706_CR47","doi-asserted-by":"publisher","first-page":"e930","DOI":"10.1212\/WNL.0000000000012438","volume":"97","author":"M Rossi","year":"2021","unstructured":"Rossi M, Baiardi S, Teunissen CE, Quadalti C, van de Beek M, Mammana A et al (2021) Diagnostic value of the CSF \u03b1-synuclein real-time quaking-induced conversion assay at the prodromal MCI stage of dementia with Lewy bodies. Neurology 97:e930\u2013e940. https:\/\/doi.org\/10.1212\/WNL.0000000000012438","journal-title":"Neurology"},{"key":"2706_CR48","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1186\/s40478-021-01282-8","volume":"9","author":"MJ Russo","year":"2021","unstructured":"Russo MJ, Orru CD, Concha-Marambio L, Giaisi S, Groveman BR, Farris CM et al (2021) High diagnostic performance of independent alpha-synuclein seed amplification assays for detection of early Parkinson\u2019s disease. Acta Neuropathol Commun 9:179. https:\/\/doi.org\/10.1186\/s40478-021-01282-8","journal-title":"Acta Neuropathol Commun"},{"key":"2706_CR49","doi-asserted-by":"crossref","unstructured":"Rutledge J, Lehallier B, Zarifkar P, Losada PM, Ryman S, Yutsis M et al (2022) Aromatic l-amino acid decarboxylase is a novel fluid biomarker of Parkinson\u2019s disease. 2022.11.09.22282149","DOI":"10.1101\/2022.11.09.22282149"},{"key":"2706_CR50","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1186\/s13023-015-0244-7","volume":"10","author":"F Sabourdy","year":"2015","unstructured":"Sabourdy F, Mourey L, Le Trionnaire E, Bednarek N, Caillaud C, Chaix Y et al (2015) Natural disease history and characterisation of SUMF1 molecular defects in ten unrelated patients with multiple sulfatase deficiency. Orphanet J Rare Dis 10:31. https:\/\/doi.org\/10.1186\/s13023-015-0244-7","journal-title":"Orphanet J Rare Dis"},{"key":"2706_CR51","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1006\/mthe.2001.0466","volume":"4","author":"R S\u00e1nchez-Pernaute","year":"2001","unstructured":"S\u00e1nchez-Pernaute R, Harvey-White J, Cunningham J, Bankiewicz KS (2001) Functional effect of adeno-associated virus mediated gene transfer of aromatic l-amino acid decarboxylase into the striatum of 6-OHDA-Lesioned Rats. Mol Ther 4:324\u2013330. https:\/\/doi.org\/10.1006\/mthe.2001.0466","journal-title":"Mol Ther"},{"key":"2706_CR52","doi-asserted-by":"publisher","first-page":"1504","DOI":"10.1002\/mds.27193","volume":"32","author":"SA Schneider","year":"2017","unstructured":"Schneider SA, Alcalay RN (2017) Neuropathology of genetic synucleinopathies with Parkinsonism\u2014review of the literature. Mov Disord Off J Mov Disord Soc 32:1504\u20131523. https:\/\/doi.org\/10.1002\/mds.27193","journal-title":"Mov Disord Off J Mov Disord Soc"},{"key":"2706_CR53","doi-asserted-by":"publisher","first-page":"1593","DOI":"10.1002\/mds.23774","volume":"26","author":"T Shachar","year":"2011","unstructured":"Shachar T, Bianco CL, Recchia A, Wiessner C, Raas-Rothschild A, Futerman AH (2011) Lysosomal storage disorders and Parkinson\u2019s disease: Gaucher disease and beyond. Mov Disord 26:1593\u20131604. https:\/\/doi.org\/10.1002\/mds.23774","journal-title":"Mov Disord"},{"key":"2706_CR54","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1002\/ana.21610","volume":"65","author":"LM Shaw","year":"2009","unstructured":"Shaw LM, Vanderstichele H, Knapik-Czajka M, Clark CM, Aisen PS, Petersen RC et al (2009) Cerebrospinal fluid biomarker signature in Alzheimer\u2019s disease neuroimaging initiative subjects. Ann Neurol 65:403\u2013413. https:\/\/doi.org\/10.1002\/ana.21610","journal-title":"Ann Neurol"},{"key":"2706_CR55","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1016\/S1474-4422(23)00109-6","volume":"22","author":"A Siderowf","year":"2023","unstructured":"Siderowf A, Concha-Marambio L, Lafontant D-E, Farris CM, Ma Y, Urenia PA et al (2023) Assessment of heterogeneity among participants in the Parkinson\u2019s Progression Markers Initiative cohort using \u03b1-synuclein seed amplification: a cross-sectional study. Lancet Neurol 22:407\u2013417. https:\/\/doi.org\/10.1016\/S1474-4422(23)00109-6","journal-title":"Lancet Neurol"},{"key":"2706_CR56","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1002\/ana.24261","volume":"76","author":"B-A Sieber","year":"2014","unstructured":"Sieber B-A, Landis S, Koroshetz W, Bateman R, Siderowf A, Galpern WR et al (2014) Prioritized research recommendations from the National Institute of Neurological Disorders and Stroke Parkinson\u2019s Disease 2014 conference. Ann Neurol 76:469\u2013472. https:\/\/doi.org\/10.1002\/ana.24261","journal-title":"Ann Neurol"},{"key":"2706_CR57","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1001\/jama.2023.13239","volume":"330","author":"JR Sims","year":"2023","unstructured":"Sims JR, Zimmer JA, Evans CD, Lu M, Ardayfio P, Sparks J et al (2023) Donanemab in early symptomatic Alzheimer disease: the TRAILBLAZER-ALZ 2 randomized clinical trial. JAMA 330:512\u2013527. https:\/\/doi.org\/10.1001\/jama.2023.13239","journal-title":"JAMA"},{"key":"2706_CR58","unstructured":"Simuni T, Chahine L, Poston K, Brumm M, Buracchio T, Campbell M et al (2023) Biological definition of neuronal alpha-synuclein disease: towards an integrated staging system for research"},{"key":"2706_CR59","unstructured":"SomaLogic (2020) SomaScan\u00ae v4 data standardization"},{"key":"2706_CR60","unstructured":"SomaLogic SOMAscan\u00ae v4 data standardization and file specification technical note"},{"key":"2706_CR61","unstructured":"SomaLogic technical specification: adaptive normalization using maximum likelihood"},{"key":"2706_CR62","doi-asserted-by":"publisher","first-page":"704","DOI":"10.1016\/S1474-4422(08)70162-5","volume":"7","author":"JA Sonnen","year":"2008","unstructured":"Sonnen JA, Montine KS, Quinn JF, Kaye JA, Breitner JCS, Montine TJ (2008) Biomarkers for cognitive impairment and dementia in elderly people. Lancet Neurol 7:704\u2013714. https:\/\/doi.org\/10.1016\/S1474-4422(08)70162-5","journal-title":"Lancet Neurol"},{"key":"2706_CR63","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1002\/ana.1232","volume":"50","author":"PC Su","year":"2001","unstructured":"Su PC, Ma Y, Fukuda M, Mentis MJ, Tseng H-M, Yen R-F et al (2001) Metabolic changes following subthalamotomy for advanced Parkinson\u2019s disease. Ann Neurol 50:514\u2013520. https:\/\/doi.org\/10.1002\/ana.1232","journal-title":"Ann Neurol"},{"key":"2706_CR64","doi-asserted-by":"publisher","DOI":"10.1111\/acel.12799","volume":"17","author":"T Tanaka","year":"2018","unstructured":"Tanaka T, Biancotto A, Moaddel R, Moore AZ, Gonzalez-Freire M, Aon MA et al (2018) Plasma proteomic signature of age in healthy humans. Aging Cell 17:e12799. https:\/\/doi.org\/10.1111\/acel.12799","journal-title":"Aging Cell"},{"key":"2706_CR65","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1016\/S1474-4422(21)00030-2","volume":"20","author":"E Tolosa","year":"2021","unstructured":"Tolosa E, Garrido A, Scholz SW, Poewe W (2021) Challenges in the diagnosis of Parkinson\u2019s disease. Lancet Neurol 20:385\u2013397. https:\/\/doi.org\/10.1016\/S1474-4422(21)00030-2","journal-title":"Lancet Neurol"},{"key":"2706_CR66","doi-asserted-by":"publisher","first-page":"2649","DOI":"10.1002\/mds.23429","volume":"25","author":"CL Tomlinson","year":"2010","unstructured":"Tomlinson CL, Stowe R, Patel S, Rick C, Gray R, Clarke CE (2010) Systematic review of levodopa dose equivalency reporting in Parkinson\u2019s disease. Mov Disord 25:2649\u20132653. https:\/\/doi.org\/10.1002\/mds.23429","journal-title":"Mov Disord"},{"key":"2706_CR67","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1038\/s43587-021-00064-0","volume":"1","author":"KA Walker","year":"2021","unstructured":"Walker KA, Chen J, Zhang J, Fornage M, Yang Y, Zhou L et al (2021) Large-scale plasma proteomic analysis identifies proteins and pathways associated with dementia risk. Nat Aging 1:473\u2013489. https:\/\/doi.org\/10.1038\/s43587-021-00064-0","journal-title":"Nat Aging"},{"key":"2706_CR68","doi-asserted-by":"crossref","unstructured":"Wei R, Wang J (2018) multiROC: calculating and visualizing ROC and PR curves across multi-class classifications","DOI":"10.32614\/CRAN.package.multiROC"},{"key":"2706_CR69","doi-asserted-by":"publisher","first-page":"1851","DOI":"10.1038\/s41591-019-0665-2","volume":"25","author":"SA Williams","year":"2019","unstructured":"Williams SA, Kivimaki M, Langenberg C, Hingorani AD, Casas JP, Bouchard C et al (2019) Plasma protein patterns as comprehensive indicators of health. Nat Med 25:1851\u20131857. https:\/\/doi.org\/10.1038\/s41591-019-0665-2","journal-title":"Nat Med"}],"container-title":["Acta Neuropathologica"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00401-024-02706-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00401-024-02706-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00401-024-02706-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,14]],"date-time":"2024-11-14T03:40:31Z","timestamp":1731555631000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00401-024-02706-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3,11]]},"references-count":69,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024,6]]}},"alternative-id":["2706"],"URL":"https:\/\/doi.org\/10.1007\/s00401-024-02706-0","relation":{},"ISSN":["0001-6322","1432-0533"],"issn-type":[{"value":"0001-6322","type":"print"},{"value":"1432-0533","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,3,11]]},"assertion":[{"value":"18 January 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 February 2024","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 February 2024","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 March 2024","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"J.R., T.W-C, B.L., and K.P. have filed a patent application related to this work. J.R. and T.W-C. are advisors of Teal Omics, where they have an equity stake. K.P. is on the Scientific Advisory Board for Curasen, where she receives consulting fees and stock options. K.P. is on the Scientific Advisory Board for Amprion, where she receives stock options.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}],"article-number":"52"}}